Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Acquires Rights to Investigational Heart Attack Drug from Bayer

NEW YORK, Nov. 17 (GenomeWeb News) - DeCode Genetics said this week that it has acquired from Bayer the exclusive worldwide rights to a small molecule compound active against a target made by a gene that predisposes to myocardial infarction.

 

Under the deal, Bayer will be paid clinical development milestones, as well as royalties on future sales of the drug.

 

DeCode said that it plans to begin testing the compound, called DG031, for efficacy in a phase II trial beginning in early 2004. Additional information about the investigational drug, said DeCode, will be made available in a scientific paper that will be submitted for publication at the beginning of the study.

 

"This is a transforming event for DeCode," DeCode CEO Kari Stefansson said in a statement. "By licensing an existing compound already found to be well-tolerated, designed against one of our key targets in myocardial infarction, we will be able to leapfrog several stages in the drug development process."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.